Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3790244 | 0.83 | CA1 (0.58) | CA1CA2CA7CA9CA12 | |
| SCHEMBL6865460 | 0.79 | NQO2 (0.41) | CA1CA2CA7CA9CA12 | |
| SCHEMBL23074907 | 0.78 | MRGPRX4 (0.46) | ALDH1A1KDM4ELMNACYP3A4MAPT | |
| SCHEMBL10731275 | 0.77 | CA1 (0.46) | CA1CA2CA7CA9CA12 | |
| SCHEMBL7099004 | 0.77 | MCHR1 (0.39) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL7100608 | 0.77 | MRGPRX4 (0.48) | ALDH1A1KDM4ELMNAMAPTHPGD | |
| SCHEMBL7930018 | 0.76 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL78713 | 0.76 | CA12 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL30772335 | 0.76 | CA12 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29424769 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0749973-B1 | Novel bisphosphines as catalysts for asymmetric reactions | BAYER AG (DE) | 2001-11-14 | — | — | EP | claimed |
| WO-2025132946-A1 | PHENYLPYRROLIDINE DERIVATIVES AND THEIR USE AS POI-THETA DERIVATIVES | BREAKPOINT THERAPEUTICS GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| CN-115850263-B | 2, 7-Disubstituted benzothiazole compound and application thereof | 浙江工业大学 | 2025-06-17 | — | — | CN | disclosed |
| US-20250066357-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12187721-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-114341124-B | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2024-09-20 | — | — | CN | disclosed |
| EP-3867238-B1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-115850263-A | 2, 7-disubstituted benzothiazole compound and application thereof | 浙江工业大学 | 2023-03-28 | — | — | CN | disclosed |
| CN-114341124-A | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20210380582-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2021-12-09 | — | — | US | disclosed |
| CN-1913898-A | Substituted piperazines | CHEMOCENTRYX INC (US) | 2007-02-14 | — | — | CN | disclosed |
| WO-2006121218-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | WO | disclosed |
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| US-6133268-A | 1,4-disubstituted piperazines | NOVO NORDISK A/S (DK) | 2000-10-17 | — | — | US | disclosed |
| US-6040302-A | ANTIINFLAMMATORY AGENTS TREATING RHEUMATOID ARTHRITIS, MIGRAINE OR ITCHING, INSULIN RESISTANCE IN NON-INSULIN-DEPENDENT DIABETES MELLITUS AND AGEING-ASSOCIATED OBESITY | NOVO NORDISK A/S (DK) | 2000-03-21 | — | — | US | disclosed |
| EP-0934312-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| US-5916889-A | ANTIDIABETIC AGENT; DIETETICS | NOVO NORDISK A/S (DK) | 1999-06-29 | — | — | US | disclosed |
| US-5801261-A | Bisphosphines as catalysts for asymmetric reactions | BAYER AKTIENGESELLSCHAFT (DE) | 1998-09-01 | — | — | US | disclosed |
| WO-1998015548-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
| US-5710339-A | REACTION OF PHOSPHOROUS OXYCHLORIDE WITH 5-BROMO-2-CHLORO ANISOLE AND REACTION WITH GRIGNARD REAGENT, LITHIUM AMIDE AND IODINE FOR DIMERIZATION THEN COMPLEXING | BAYER AKTIENGESELLSCHAFT (DE) | 1998-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066357-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | CA1 1959/4885CA2 1040/4885CA7 1637/4885 |
| US-12187721-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PTP4A1, PPP5C | CA1 1771/4885CA2 999/4885CA7 1369/4885 |
| US-20210380582-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PTP4A1, PPP5C | CA1 1771/4885CA2 999/4885CA7 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.